Sign in

Research summary ·

Impact of Botulinum Toxin on Ocular Surface Parameters in Patients With Orbicularis Spasm: A Systematic Review and Meta-Analysis.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This review pooled earlier studies on botulinum toxin (BTX) shots. The shots treat spasms of the eyelid muscle. People in the studies had blepharospasm or hemifacial spasm. The team searched research records up to June 2025. Each study had at least 7 people, tested before and after the shots. Tests looked at tears, dry eye symptoms, eye surface damage and astigmatism. In all, the studies held 820 people and 1147 eyes.

What they found

Dry eye symptom scores got better at 1 to 4 weeks. The scores were still better at 3 months. At 3 months, the tear film also lasted longer before it broke up. The amount of tears did not change. Staining of the eye surface did not change either. More shot sites were tied to more tears at 1 month. BTX was also linked to a small drop in astigmatism.

What it means for patients

The authors say BTX eases eye surface symptoms in these spasms. They say it may also make the tear film more stable. But they think the gains may come from fewer eyelid spasms. So the results do not show that BTX acts on the eye surface itself.

Why it is not certain yet

The authors say these effects likely come from fewer eyelid spasms. The cause is not yet clear. They call for new studies with exact tests of the eye and the spasms. The pooled data looked at one group, before and after shots, with no comparison group. A review can only be as good as the studies in it.

Source

Impact of Botulinum Toxin on Ocular Surface Parameters in Patients With Orbicularis Spasm: A Systematic Review and Meta-Analysis.

PubMed · PMID 42749245

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Dystonia publications